Latest market price
13.65
-0.50-3.53%
OverviewShort InterestFilings
SNDXQT31Syndax Pharmaceuticals, Inc.·NASDAQ
13.65-3.53%
Earnings
Down 3.5% — Reported earnings — EPS missed by 23%, revenue missed by 8%.
High confidence
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
TRAX-0.33%$45.08NVAX-3.72%$10.08NUVB-0.21%$4.76KLRA-4.10%$12.86REPL+1.27%$17.61STOK-0.23%$26.29QURE-1.86%$24.83NTLA-5.74%$12.47
Snapshot
Index—P/E—EPS (ttm)-2.52Insider Own5.58%Shs Outstand89.30MPerf Week1.87%
Market Cap1.22BForward P/E—EPS next Y-0.82Insider Trans-2.29%Shs Float80.30MPerf Month-25.08%
Enterprise Value1.26BPEG—EPS next Q-0.48Short Float22.42%Perf Quarter-29.05%
Income-221.00MP/S4.84EPS this Y—Short Ratio10.82Perf Half Y-28.57%
Sales252.00MP/B81.25EPS next Y—ROA-31.37%Short Interest18.00MPerf YTD-35.03%
Book/sh0.17P/C2.22EPS next 5Y—ROE-372.94%52W High25.59 -46.66%Perf Year3.25%
Cash/sh6.14P/FCF—EPS past 3/5Y—ROIC-32.10%52W Low12.80 6.64%Perf 3Y14.90%
Dividend Est.—EV/EBITDA—Sales past 3/5Y— 143.72%Gross Margin97.47%Volatility5.36% 4.73%Perf 5Y-28.01%
Dividend TTM—EV/Sales5.00EPS Y/Y TTM—Oper. Margin-77.05%ATR (14)0.77Perf 10Y-9.72%
Dividend Ex-Date—Quick Ratio6.44Sales Y/Y TTM218.99%Profit Margin-87.60%RSI (14)35.75Recom2.09
Dividend Gr. 3/5Y—Current Ratio6.77EPS Q/Q33.73%SMA20-6.57%Beta0.46Target Price36.67
Payout0.00%Debt/Eq39.27Sales Q/Q92.11%SMA50-20.56%Rel Volume1.29Prev Close14.15
Employees298LT Debt/Eq39.27EarningsNov 02SMA200-32.54%Avg Volume1.97MPrice13.65
IPO DateMar 02, 2016Option/ShortYes / YesEPS/Sales Surpr.-22.86% -8.29%Net Debt/EBITDA—Volume2,539,601Change-3.53%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-29-26ReiteratedJefferies$37 → $35
Aug-21-26ReiteratedUBSBuy$38 → $33
Aug-05-26ReiteratedHC Wainwright & Co.Buy$40 → $38
Jun-12-26ReiteratedGuggenheimBuy$34 → $31
Jun-03-26ReiteratedH.C. WainwrightBuy$33 → $40
May-04-26ReiteratedStifel Nicolaus$45 → $46
May-01-26ReiteratedBarclaysOverweight$35 → $37
Feb-27-26ReiteratedStifel Nicolaus$44 → $45
Nov-24-25ReiteratedBarclaysOverweight$22 → $35
Nov-04-25ReiteratedBarclaysOverweight$33 → $22
Latest News· Times ET
Oct-30-26
Oct-30-2609:01AM
Syndax's Revuforj® (revumenib) Wins Prestigious 2026 Prix Galien USA Award for Best Product for Rare/Orphan Diseasesglobenewswire.com
07:00AM
Syndax Announces Participation in November Investor Conferencesglobenewswire.com
Oct-29-26
Oct-29-2610:00AM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDXprnewswire.com
Oct-28-26
Oct-28-2609:00AM
Earnings Preview: Niagen Bioscience (NAGE) Q3 Earnings Expected to DeclineYahoo
Oct-26-26
Oct-26-2611:01AM
Syndax Pharmaceuticals (SNDX) May Report Negative Earnings: Know the Trend Ahead of Q3 Releasezacks.com
07:00AM
Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026globenewswire.com
04:57AM
Syndax Pharmaceuticals (SNDX) Set to Announce Quarterly Earnings on Mondaydefenseworld.net
Oct-21-26
Oct-21-2604:15AM
Contrasting BioCryst Pharmaceuticals (NASDAQ:BCRX) & Syndax Pharmaceuticals (NASDAQ:SNDX)defenseworld.net
Oct-17-26
Oct-17-2609:22PM
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Lawbusinesswire.com
Oct-15-26
Oct-15-2604:01PM
Syndax's Revuforj® (revumenib) Named to TIME's Best Inventions of 2026 Listglobenewswire.com
Oct-14-26
Oct-14-2610:56AM
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goalzacks.com
Oct-13-26
Oct-13-2611:00PM
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)gurufocus.com
12:24PM
Syndax Pharmaceuticals Suffers Pipeline Blowbenzinga.com
04:02AM
Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday’s Pre-Market SessionBenzinga
Oct-12-26
Oct-12-2604:01PM
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosisglobenewswire.com
Company

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue252172240—————
Cost of Goods Sold Incl. D&A6710—————
Gross Profit246165230—————
Selling, General and Administrative Excl. Other17518012167—————
Research and Development262259242163—————
Other Operating Expense3-100—————
Operating Income-194-273-340-230—————
Interest Expense863450—————
Unusual Expense
—————————
Non-Operating Income (Expense)58212621—————
Net Income Before Taxes-221-285-319-209—————
Income Taxes
0000—————
Consolidated Net Income-221-285-319-209—————
Net Income From Continuing Operations-221-285-319-209—————
Net Income-221-285-319-209—————
EPS (Recurring)-2.52-3.29-3.73-2.98—————
EPS (Basic, Before Extraordinaries)-2.52-3.29-3.73-2.98—————
EPS (Diluted)-2.52-3.29-3.73-2.98—————
EBITDA-135-252-314-209—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio4.8210.6347.37——————
Gross Margin97.6295.9395.83——————
Operating Margin-76.98-158.72-1,416.67——————
Net Margin-87.70-165.70-1,329.17——————
Shares Outstanding89878670—————
Market Capitalization1,2151,8281,1371,513—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$26.99$23.01$19.02$15.04$11.06● Close Price0.00M0.33M0.67M1.00M1.34MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Podlesak DennisDirectorOct 29 '26Option Exercise11.818,00094,480247,763Oct 30
Podlesak DennisDirectorOct 29 '26Sale14.218,000113,716239,763Oct 30
Metzger Michael AChief Executive OfficerJul 08 '26Sale24.2432,375784,776484,843Jul 09
Metzger Michael AChief Executive OfficerJul 08 '26Option Exercise6.3864,750413,106517,218Jul 09
Botwood Nicholas A.J.Head of R&D, CMOJun 12 '26Sale18.1431,235566,60360,885Jun 12
Botwood Nicholas A.J.Head of R&D, CMOJun 12 '26Option Exercise13.8262,470863,33692,120Jun 12
Botwood Nicholas A.J.Head of R&D, CMOJun 11 '26Option Exercise13.8222,515311,15795,165Jun 12
Botwood Nicholas A.J.Head of R&D, CMOJun 11 '26Sale18.0034,280617,04060,885Jun 12
Goldan Keith A.Chief Financial OfficerJun 01 '26Sale18.991,17722,351139,252Jun 02
Metzger Michael AChief Executive OfficerJun 01 '26Sale18.996,847130,025484,843Jun 02
Metzger Michael AChief Executive OfficerFeb 09 '26Sale21.0317,159360,819491,690Feb 10
Goldan Keith A.Chief Financial OfficerFeb 09 '26Sale21.033,41071,705140,429Feb 10
Goldan Keith A.Chief Financial OfficerFeb 06 '26Sale20.622,08242,931143,839Feb 06
Metzger Michael AChief Executive OfficerFeb 06 '26Sale20.627,412152,835508,849Feb 06
Metzger Michael AChief Executive OfficerSep 08 '25Option Exercise10.90314,6143,429,292455,968Sep 08
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.